巨噬细胞活化标志物可溶性CD163是人类免疫缺陷病毒/丙型肝炎病毒共感染中肝纤维化的动态标志物
该研究回顾性分析HIV/HCV共感染、HCV单感染和HIV单感染患者抗病毒治疗前后的血清sCD163和肝组织CD163表达。HIV/HCV共感染者sCD163显著高于任一单感染组,成功抗病毒治疗后下降但未完全正常化。sCD163与坏死性炎症、Ishak纤维化评分和无创纤维化评分相关,在轻至中度纤维化阶段随纤维化评分升高而递增,至4期达峰后平台,提示sCD163是纤维化生成而非累积纤维化的动态标志物。
要点
- HIV/HCV共感染者sCD163显著高于HCV或HIV单感染,成功抗病毒治疗后下降但未完全正常化。
- sCD163与坏死性炎症、Ishak纤维化评分及无创纤维化评分相关,随Ishak评分递增至4期达峰后平台。
- 仅轻至中度纤维化者HIV/HCV共感染sCD163高于HCV单感染,提示HIV相关巨噬细胞活化加速纤维化进展。
核心结论
- 在HIV/HCV共感染中,sCD163水平升高伴随轻至中度纤维化时门管区CD163+巨噬细胞增多,但在 established cirrhosis 中未见此现象,提示sCD163是纤维化生成的动态标志物而非累积纤维化的标志物。
- 研究结果提示HIV相关巨噬细胞活化可能参与HIV/HCV共感染中纤维化加速进展。
研究设计与样本
- 回顾性分析HIV/HCV共感染、HCV单感染和HIV单感染患者抗病毒治疗前后的血清sCD163(酶联免疫吸附试验)和肝组织CD163(免疫荧光CD163/CD68共染色)。
主要发现
- HIV/HCV共感染者sCD163显著高于HCV或HIV单感染组,成功抗病毒治疗后下降但未完全正常化。
- 在HIV/HCV共感染中,sCD163与坏死性炎症、Ishak纤维化评分和无创纤维化评分相关。
- sCD163水平随Ishak纤维化评分递增而逐步升高,至4期达峰后平台。
- 门管区CD163+巨噬细胞频率随纤维化评分升高而增高。
- 按纤维化分期分层后,仅轻至中度纤维化者HIV/HCV共感染sCD163高于HCV单感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coinfection with human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV)-related liver fibrosis. Macrophages are triggered during both viral infections and are critical in liver inflammation/fibrogenesis. Liver fibrosis strongly associates with serum soluble CD163 (sCD163, a macrophage activation marker); comprehensive evaluation in HIV/HCV coinfection is lacking. METHODS: We retrospectively analyzed sCD163 (enzyme-linked immunosorbent assay) and hepatic CD163 (immunofluorescent CD163/CD68 costaining) in patients infected with HIV/HCV, HCV, or HIV, pre- and post-antiviral therapy. RESULTS: sCD163 was significantly higher in HIV/HCV compared to either monoinfection, and decreased following successful antiviral therapy, although did not fully normalize. In HIV/HCV, sCD163 was associated with necroinflammation, Ishak fibrosis scores, and noninvasive fibrosis scores. We observed a novel trend whereby sCD163 levels progressively increase with increasing Ishak fibrosis score, peaking at stage 4, above which levels plateaued. Periportal CD163+ macrophage frequency was also higher with increasing fibrosis score. When stratified by fibrosis stage, sCD163 levels were higher in HIV/HCV than HCV but only in individuals with mild to moderate fibrosis. CONCLUSIONS: In HIV/HCV, increasing sCD163 levels accompanied periportal CD163+ macrophage enrichment in mild to moderate fibrosis, but not in established cirrhosis, suggesting that sCD163 is a dynamic biomarker of fibrogenesis rather than accumulated fibrosis. Our findings implicate HIV-related macrophage activation in accelerated fibrosis progression in HIV/HCV coinfection.
引用
- Lidofsky A, Holmes JA, Feeney ER, et al. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 2018. PMID: 29868909. doi:10.1093/infdis/jiy331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。